Providence Therapeutics Holdings Inc., VaxThera S.A.S, And The Ministry Of Health And Social Protection Of The Republic Of Colombia, Announce The Signing Of An MOU To Explore Collaborations For COVID-19 Vaccine Development

By AIT News Desk On Dec 20, 2021

Providence Therapeutics announced the signing of a Memorandum of Understanding (MOU) with VaxThera S.A.S and the Ministry of Health and Social Protection of the Republic of Colombia, to develop, produce and commercialize vaccines, including for COVID-19, in Colombia and the LATAM region. The signing took place at a ceremony presided over by President Iván Duque Márquez at the Presidential Palace in Bogota. As part of the collaboration, Providence will provide access to its first generation PTX-COVID19-B, a pipeline of vaccines against COVID variants, and its mRNA platform and associated IP for developing other vaccines against infectious diseases and oncology. VaxThera is engaged in R&D, manufacturing, and commercialization of vaccines in the region, and is currently designing a manufacturing facility to produce up to 100 million vaccines does per year. This collaboration is supported by National Health Colombia, as part of their efforts in executing public policy to develop and enhance capacity for essential medicines and ensure vaccine security in the future.

The MOU contemplates a collaboration which will make Colombia a hub in the region for manufacturing and development of vaccines, as well as the foundation for the training of technical and management personnel for the industry. The facility in Medellin envisages a R&D center for research into infectious diseases which are especially relevant to the region. The collaboration will also foster and promote alliance with local and regional entities, including academia, that may lead to the development of new technologies in Life Sciences.

President Marquez described the signing of the MOU as a “historic day for our country, because of the coming together of a Canadian company, Providence with a Colombian company, VaxThera to develop a vaccine production plant in the country, with work beginning February 2022 in Rionegro, Antioquia. This alliance with Providence will start with small batches but scale up rapidly by June of 2022″

Tessl Raises $125 Million to build AI Native Software Development

Nov 15, 2024

Team-GPT Raises $4.5Million to Discover and Deploy AI Use Cases in Enterprises

Nov 15, 2024

Ironclad Launches Jurist: an AI-Powered Assistant That Shows its Work

Nov 15, 2024

Prev Next 1 of 40,382

“This MOU is proof, that the demand for an affordable and effective COVID-19 vaccine very much exists; we are excited by the prospect of working with VaxThera to support their goal of developing, manufacturing, and commercializing medicines in Colombia. We look forward to working with National Health Colombia to commercialize PTX-COVID19-B and support the health and welfare of the people of Colombia as well as all Latin America” said Brad Sorenson, CEO, Providence Therapeutics.

“We are very excited to be collaborating with Providence Therapeutics and look forward to developing a host of effective and affordable vaccines based on the proven mRNA platform developed by Providence. In the latter, we have found a willing and capable partner who is prepared to fully transfer the latest in mRNA vaccine technology to our collaboration in Colombia” said Jorge Osario, CEO of VaxThera.

[To share your insights with us, please write to sghosh@martechseries.com]